Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-025116

Chief Accounting Officer sold 697 shares at an average $3.67 ($2,556)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-19 Sale : show line 1 in the form 10b5-1 −348 $3.71 $1,291 134,906 D
2023-04-20 Sale : show line 2 in the form 10b5-1 −349 $3.63 $1,265 134,557 D
Open-market sales · 697 sh · avg $3.67 · $2,556
Loading xslF345X04/doc4.xml…